Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...

Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease documented in less than 50 people.

More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.

The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain to support the launch of its obesity pill orforglipron.

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for ...

The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...

The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...

Belgium-based UCB said Wednesday its blockbuster anti-inflammatory drug Bimzelx beat AbbVie’s Skyrizi in a head-to-head trial for active psoriatic arthritis, potentially setting up Bimzelx for a boost ...

Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.

The Kanakee project builds on the company’s efforts to increase its U.S. footprint, where it has already spent more than $3 ...

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.